FSHD Society

FSHD Society

The FSHD Society was founded to accelerate treatments for facioscapulohumeral muscular dystrophy, the third most common inherited muscle disease. The organization is led by a team of scientific and patient advocates with offices in Manchester, New Hampshire, and additional hubs in Pasadena, Baltimore, Palo Alto, and Chicago. The Society's strategy centers on funding translational research and clinical trials, investing in biomarker discovery, and maintaining a global patient registry. It has supported multiple preclinical and phase 1 studies for candidates including losmapimod (Fulcrum Therapeutics) and other gene-silencing approaches. Geographic focus spans North America and Europe, with research collaborations in 25 countries. The organization deploys an annual budget (estimated at several million dollars) sourced from private donations, grants, and partnerships. While it does not manage third-party capital like a traditional family office, its role as a funnel for philanthropic and biotech funding makes it a key player in neuromuscular disease drug development. Feb 2025: The FSHD Society announced a new partnership with the Muscular Dystrophy Association to expand clinical trial infrastructure. The FSHD Society's structural differentiator is its direct engagement with a defined patient population — it operates both as a research funder and a community hub, giving it unique access to trial recruitment and natural-history data. This hybrid model blends nonprofit advocacy with pharmaceutical pipeline development, distinct from pure research charities or investment funds.